Balanced news tone
News Sentiment
BIIB sentiment intelligence
Biogen Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
53
Balanced news tone
27 relevant articles
Price is moving more forcefully than the current news tone suggests.
84/100 classification confidence.
directly relevant articles
high-authority source matches
+5.1% over one week, +10.3% over four weeks, trend active, and near fair-value range.
BofA cuts Biogen stock price target on higher expectations bar
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
84/100 classification
One-week reaction
5.1%
Price confirming higher
Trend fit
Trend active
10.3% over four weeks
Fair value
6.8%
Near fair-value range
Sentiment Mix
Positive, neutral, negative
Positive
5
Neutral
20
Negative
2
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
Investing.com
Direct company coverage
BofA cuts Biogen stock price target on higher expectations bar
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 21 Jul 2026 11:01
- Source
- Investing.com
simplywall.st
Direct company coverage
Biogen (BIIB) Expands Its Alzheimer’s Pipeline, Is The 9% Undervaluation Still There?
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 21 Jul 2026 07:22
- Source
- simplywall.st
Quiver Quantitative
Direct company coverage
Lobbying Update: $1,060,000 of BIOGEN lobbying was just disclosed
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 21 Jul 2026 03:07
- Source
- Quiver Quantitative
Market source
Direct company coverage
Biogen Shares Decline After Detailed Diranersen Alzheimer's Study Data
- Tone
- Negative 34/100
- Event
- Market update
- Published
- 15 Jul 2026 14:51
- Source
- Market source
Clinical Trials Arena
Direct company coverage
AAIC26: Biogen stock drops after unveiling tau-targeting ASO data
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 10:38
- Source
- Clinical Trials Arena
Market source
Direct company coverage
Biogen (BIIB) Following Fresh Alzheimer’s Data Is The Upside Story Still Intact
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 15 Jul 2026 02:11
- Source
- Market source
Fierce Biotech
Direct company coverage
Biogen defends anti-tau drug after stock slides on Alzheimer’s readout
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 14 Jul 2026 18:00
- Source
- Fierce Biotech
Market source
Direct company coverage
Here is Why Biogen (BIIB) is One of the Most Undervalued NASDAQ Stocks to Buy Right Now
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jul 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 04 Jul 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Why Biogen (BIIB) Stock Is Up Today
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 07:00
- Source
- Market source
Market source
Direct company coverage
Biogen (BIIB) Stock Could Be 10.3% Undervalued on Its Pipeline Narrative
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 19 Jun 2026 07:00
- Source
- Market source
PR Newswire
Direct company coverage
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. - BIIB
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 07:00
- Source
- PR Newswire
Biogen
Direct company coverage
Biogen Completes Acquisition of Apellis Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 May 2026 07:00
- Source
- Biogen
Market source
Direct company coverage
Biogen (BIIB) Stock Trades Up, Here Is Why
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 20 Apr 2026 07:00
- Source
- Market source
24/7 Wall St.
Direct company coverage
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, and More
- Tone
- Neutral 50/100
- Event
- Analyst action
- Published
- 14 Apr 2026 07:00
- Source
- 24/7 Wall St.
Biogen
Direct company coverage
Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
- Tone
- Positive 95/100
- Event
- Guidance
- Published
- 31 Mar 2026 07:00
- Source
- Biogen
Bloomberg.com
Direct company coverage
Biogen to Buy Apellis for $5.6 Billion to Boost Kidney Franchise
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 31 Mar 2026 07:00
- Source
- Bloomberg.com
Biogen
Direct company coverage
Biogen to Share New SMA Data at Muscular Dystrophy Association and SMA Europe Conferences
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 05 Mar 2026 12:32
- Source
- Biogen
Biogen
Direct company coverage
Biogen Completes Acquisition of Alcyone Therapeutics
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 14 Nov 2025 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Feb 2025 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Completes Acquisition of Reata Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Deals and strategy
- Published
- 26 Sep 2023 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen to Acquire Reata Pharmaceuticals
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 28 Jul 2023 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental Biologics License Application for the Potential Traditional Approval of LEQEMBI in Early Alzheimer’s Disease
- Tone
- Neutral 50/100
- Event
- Regulatory and legal
- Published
- 09 Jun 2023 07:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen and Sage Therapeutics Share Update on FDA Advisory Committee for Zuranolone
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 08 Mar 2023 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen Reaches Agreement with Samsung Biologics to Sell Equity Stake in Their Biosimilar Joint Venture for up to $2.3 billion
- Tone
- Negative 34/100
- Event
- Deals and strategy
- Published
- 27 Jan 2022 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen and Sage Therapeutics Announce Global Collaboration to Develop and Commercialize Potential Breakthrough Therapies in Depression and Movement Disorders
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Nov 2020 08:00
- Source
- Biogen
Biogen
Direct company coverage
Biogen’s Board of Directors Approves Separation of Bioverativ and Declares Special Dividend Distribution of Bioverativ Stock
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 12 Jun 2019 10:45
- Source
- Biogen